Read more in the study ‘The impact of Covid-19 on access to Parkinson’s disease medication’.
Has Covid-19 impacted access to Parkinson’s medication?
News
Author: Simge Eva DoganPublished: 17 September 2020
Prep:
Cook:
Serves:

New research has found that the coronavirus pandemic has affected access to medication for people living with Parkinson’s disease.
The sub-study used information from a survey conducted by the International Parkinson and Movement Disorder Society. The results from 346 participants showed that 22.8% of high-income and 88.9% of low-income countries’ respondents agreed that the coronavirus crisis had impacted people’s access to Parkinson’s medication. Some respondents reported increased disability, increased hospitalisation and increased mortality as factors. The majority of those who completed the survey were doctors.
The researchers concluded: “Our results offer preliminary data that the Covid-19 pandemic has affected Parkinson’s disease patients’ access to regular medication.
“Covid-19 has diverted resources away from chronic conditions towards the fight against Covid-19 in many countries. Resource-poor countries seem to be disproportionately affected compared to their affluent counterparts.”
For more information on Parkinson’s and Covid-19 please visit Parkinson’s Europe website.
Read more:
Brazilian dance could improve mobility in people with Parkinson’s, study finds
#WomenAndParkinsons shortlisted for ‘Charity Content Campaign of the Year’
Last Month
Next Month
Share this story
Related articles

Special reports
How virtual reality is giving Parkinson’s patients a ‘disease-free’ Second Life
Second Life: a (virtual) world without Parkinson’s
READ MORE
Health & Fitness
VIDEO: 5 exercises to improve Parkinson’s symptoms
Watch this exclusive exercise video that may help your symptoms
READ MORE
In my country
Pioneering ParkinsonNet programme launches in Norway
Innovative, patient-centred programme arrives in Norway
READ MORE
Comments